Following on from information provided to NICE by the company in July 2018, the appraisal of Erythrocyte encapsulated asparaginase for treating acute lymphoblastic leukaemia [ID864] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 864 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Stakeholders
| Companies sponsors | Orphan Europe |
| Others | Department of Health |
| NHS England | |
| NHS Cumbria CCG | |
| NHS Redditch and Bromsgrove CCG | |
| Welsh Government | |
| Patient carer groups | Leukaemia CARE |
| Professional groups | Association of Cancer Physicians |
| Cancer Research UK | |
| Royal College of Physicians | |
| Royal College of Radiologists | |
| Associated public health groups | None |
| Comparator companies | Shire Pharmaceuticals (pegylated asparaginase) |
| Jazz Pharmaceuticals (Erwinia-derived asparaginase) | |
| Medac GmbH (E.coli asparaginase) (no confidentiality agreement signed not participating) | |
| General commentators | British National Formulary |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Relevant research groups | Institute of Cancer Research |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 November 2022 | Discontinued. Following on from information provided to NICE by the company in July 2018, the appraisal of Erythrocyte encapsulated asparaginase for treating acute lymphoblastic leukaemia [ID864] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 27 June 2018 - 25 July 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 06 July 2018 | As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal (STA) of erythrocyte encapsulated asparaginase within its marketing authorisation for treating acute lymphoblastic leukaemia. For information, the company have now advised that they will not be pursuing a marketing authorisation application for erythrocyte encapsulated asparaginase from the European Medicines Authority for this indication at this time. Therefore, NICE have cancelled the consultation for this topic and have decided to suspend this appraisal on its work programme. As the appraisal has been referred, NICE will continue to monitor any developments and provide an update as and when the situation changes. |
| 06 July 2018 | Suspended. As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal (STA) of erythrocyte encapsulated asparaginase within its marketing authorisation for treating acute lymphoblastic leukaemia. For information, the company have now advised that they will not be pursuing a marketing authorisation application for erythrocyte encapsulated asparaginase from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to cancel the consultation for this topic at this time and suspend this appraisal on its work programme. As the appraisal has been referred, NICE will continue to monitor any developments and provide an update as and when the situation changes. |
| 05 July 2018 | As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal (STA) of erythrocyte encapsulated asparaginase within its marketing authorisation for treating acute lymphoblastic leukaemia. For information, the company have now advised that they will not be pursuing a marketing authorisation application for erythrocyte encapsulated asparaginase from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal on its work programme. We have therefore cancelled the consultation for this topic at this stage. As the appraisal has been referred, NICE will continue to monitor any developments and provide an update as and when the situation changes. |
| 28 October 2016 | Suspended. the company that markets the technology has informed NICE of a delay to regulatory proceedings, therefore they will not provide an evidence submission for this appraisal at this time. NICE will suspend this appraisal and provide further updates when they are available. |
| 08 August 2016 | Invitation to participate |
| 01 April 2016 | Draft scope documents |
| 15 March 2016 | Referral |
| 15 March 2016 | In progress. DHSC referral received |
For further information on our processes and methods, please see our CHTE processes and methods manual